News for CymaBay Therapeutics, Inc. (0I5P.L)

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take a look at where Gilead Sciences, Inc.

The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its investment programs.

We recently published a list of 15 Best NASDAQ Dividend Stocks To Buy. In this article, we are going to take a look at where Gilead Sciences, Inc.

Macroeconomic factors have weighed on US stocks in the final days of the year, with the broader market declining by over 1% in the past week.

Advancements and Projections in the Pharmaceutical Intermediates Market: Insights, Trends, Opportunities, and Recent Developments...

Gilead's adjusted EPS and revenue growth is currently expected to be 2.9%. Read why the market's lack of enthusiasm for GILD stock is understandable.

Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis

Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis

Drug blockbusters facing key patent expirations and Big Pharma's surplus of cash suggest increased M&A volume in the coming year. Click here to read our picks.

Gilead Sciences will report its Q1 2024 earnings on Thursday, April 25. Check out whether GILD stock is a good buy ahead of Q1 earnings.

The rise in the number of people suffering from cirrhosis can be attributed to rapidly changing lifestyles such as an increase in alcohol consumption and...

As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.  U.S. FDA accepted...